Bayer stock reacts to JP Morgan Overweight call and FDA patch update
Published on 09/04/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer stock (ISIN DE000BAY0017) is trading close to the 49-euro level on Xetra on September 4, 2026, with intraday moves between about 48.42 euros and 49.59 euros as investors digest new analyst input and regulatory headlines from the United States.
Analyst view supports Bayer stock
According to an analysis summary compiled by finanzen.at, JP Morgan Chase & Co. reaffirmed its Overweight rating on Bayer with a price target of 61.00 euros on September 3, 2026, implying upside of about 23 percent versus a reference level around 49.49 euros.
The same analysis notes that the Overweight stance is underpinned by Bayer’s five-year planning for its agricultural division, with the bank highlighting that management confirmed the roadmap for launching the next generation of key products in the crop science segment.
Recent price action and market context
Intraday market data compiled by finanzen.ch show that Bayer shares on Xetra traded at 48.89 euros at 4:28 PM on September 4, 2026, down 0.9 percent from the opening level of 48.97 euros, after touching an intraday low of 48.42 euros and an earlier high of 49.59 euros.
An earlier snapshot from the same portal indicates that at 9:28 AM on September 4, 2026, Bayer stock was up 0.5 percent at 49.59 euros compared with its Xetra opening price of 48.97 euros, underlining how the shares faded from morning strength to modest afternoon losses as trading progressed.
More Bayer stock context
Investors can follow additional Bayer stock news and historical performance data via the issuer overview and dedicated topic pages.
Crop science strategy and product pipeline
The JP Morgan assessment summarized by finanzen.at points out that Bayer’s crop science division plans to bring ten significant new products to market over the next few years, and that the first of these blockbuster candidates in the insecticide segment is already being introduced in key agricultural markets.
From an investor perspective, this multi-year pipeline in crop protection and seeds is crucial because the bank explicitly ties its Overweight rating and 61-euro price target to the execution of this agricultural growth strategy rather than to short-term earnings volatility.
FDA comments on estradiol patch supply
A separate regulatory angle emerged on September 4, 2026, when a daily European equity briefing compiled by Newsquawk highlighted that the US Food and Drug Administration is working with manufacturers, including Bayer, to increase the supply of estradiol transdermal patches after reports of patient access difficulties.
The same briefing mentions Bayer alongside Sandoz as companies whose products are part of the estradiol patch segment, signaling that regulators view these manufacturers as important partners when tackling supply constraints in hormone therapy for patients.
Representative product: estradiol transdermal patch
Against this backdrop, the estradiol transdermal patch stands out as a representative product in Bayer’s pharmaceutical portfolio because the FDA’s efforts to secure adequate supply directly involve Bayer and underscore the clinical relevance of this hormone replacement therapy.
Bayer stock price snapshot
Based on intraday Xetra data cited by finanzen.ch, Bayer stock last traded at 48.89 euros in the late afternoon on September 4, 2026, which places the shares near the lower end of the day’s observed range between 48.42 euros and 49.59 euros and below JP Morgan’s 61-euro price target that assumes successful execution of the crop science growth plan.
Bayer stock key data
- Company: Bayer Aktiengesellschaft
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Trading venue: Xetra
- Price (as of September 4, 2026, 16:28): 48.89 EUR
- Sector / Industry: Healthcare / Pharmaceuticals and Crop Science
- Index membership: DAX
